Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Psychopharmacology – March 07, 2022
Source: OpenAlex
Summary
A systematic review highlights that 70% of studies on MDMA and psilocybin focus on their potential in psychiatry, showcasing promising therapeutic effects. Analyzing data from over 1,000 participants, the review emphasizes the importance of understanding drug-drug interactions with these psychoactive substances. Both MDMA and psilocybin show significant influence on neurotransmitter receptors, which could enhance treatment outcomes for various mental health conditions. This comprehensive overview aids in ensuring safe integration of these hallucinogens into modern medicine.
Abstract
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.